Profadol
- none
- US: Analogue to a Schedule I/II drug (Analogue of Tapentadol, Schedule II)
- 3-(1-methyl-3-propyl-pyrrolidin-3-yl)phenol
- 428-37-5
- 9882
- 9498
- 41GDG43FTT
- ChEMBL161204
- DTXSID30861924
Profadol (CI-572) is an opioid analgesic which was developed in the 1960s by Parke-Davis.[1] It acts as a mixed agonist-antagonist of the μ-opioid receptor. The analgetic potency is about the same as of pethidine (meperidine), the antagonistic effect is 1/50 of nalorphine.[2]
Synthesis
The Knoevenagel condensation between 3'-Methoxybutyrophenone [21550-06-1] and Ethyl cyanoacetate gives (1). Conjugate addition of cyanide gives (2). Hydrolysis of both nitrile groups, saponification of the ester and decarboxylation gives the diacid, CID:164137621 (3). Imide formation occurs upon treatment with methylamine giving 3-(3-Methoxyphenyl)-1-methyl-3-propylpyrrolidine-2,5-dione, CID:163444474 (4). Reduction of the imide by lithium aluminium hydride gave [1505-32-4][29369-01-5] (5). Demethylation completed the synthesis of Profadol (6).
See also
References
- ^ DE 1303096
- ^ Schröder E, Rufer C, Schmiechen R (1976). Arzneimittelchemie 1. Grundlagen, Nerven, Muskeln und Gewebe. Stuttgart: Georg Thieme Verlag. ISBN 3-13-520601-7.
- ^ Cavalla, J. F.; Jones, R.; Welford, M.; Wax, J.; Winder, C. V. (1964). "Analgetics Based on the Pyrrolidine Ring. III". Journal of Medicinal Chemistry. 7 (4): 412–415. doi:10.1021/jm00334a005.
- ^ John Frederick Cavalla & Alan Chapman White, DE 1272296 (1968 to Parke Davis and Co LLC).
- ^ Cavalla John Frederick, U.S. patent 3,149,123 (1964 to Parke Davis and Co LLC).
- v
- t
- e
modulators
Calcium blockers |
|
---|---|
Sodium blockers |
|
Potassium openers |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III